diabetic kidney disease stage 3
Conditions
Interventions
Control group:Placebo
Sponsors
Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who are clinically diagnosed as DKD and meet the criteria of DKD Mogensen III liver and kidney yin deficiency and blood stasis syndrome established in this project, and kidney damage caused by non-DKD diseases is excluded; (2) Aged 18-75 years old; (3) Serum creatinine was relatively stable within 3 months before enrollment, and the change did not exceed 15%; (4) Reduce blood pressure by Western medicine, and introduce the end-of-period sitting resting diastolic blood pressure (DBP) <=90mmHg and the sitting resting systolic pressure (SBP) <=160mmHg; after basic hypoglycemic, the introduction of end-period glycosylated hemoglobin (HbA1c) is between 6-9%; (5) Accept treatment voluntarily and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with type 1 diabetes; (2) Those who have acute complications of diabetes and urinary tract infection within 1 month; (3) Severe heart, brain, liver, and hematopoietic system and other serious diseases (cerebral infarction, cerebral hemorrhage, transient ischemic attack, myocardial infarction, unstable angina, heart failure, elevated transaminases) occurred in the 3 months before enrollment Up to 2 times the upper limit of the normal range) and those who have used glucocorticoids or immunosuppressants; (4) Those who have had active bleeding in 3 months; (5) Abnormal blood coagulation function; (6) Those with renal artery stenosis; (7) Pregnant or lactating women, or those who are preparing to become pregnant; (8) People with mental illness or cognitive impairment; (9) People with allergies or allergic to the components of the drug; (10) Participants in other clinical trials within 1 month before enrollment; (11) The investigator believes that others are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urine albumin creatine ratio;urinary albumin excretion rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| BUN;Quality of Life;Cys-c;CRP;serum creatinine concentration;TCM symptom score;fasting blood glucose;TNF-alpha;TC;UA;LDL-c;HbA1C;IL-6;eGFR;TG;HDL-c;IL-1;2hBG; | — |
Countries
China
Contacts
Public ContactXu Jiangyan
Henan University of Chinese Medicine
Outcome results
None listed